ArticleArquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery2026
Association between KRAS gene mutation and clinicopathological factors in patients with metastatic colorectal cancer.
Article in Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer is a global health problem with high incidence and mortality rates, frequently diagnosed at metastatic stages. Mutations in the KRAS gene play a key role in colorectal cancer progression, significantly influencing treatment resistance and prognosis.
aimsThis study investigated the association between clinicopathological characteristics and KRAS mutations in patients with metastatic colorectal cancer.
methodsThis retrospective study evaluated medical records of patients with metastatic colorectal carcinoma who underwent KRAS gene mutation testing. A total of 96 patients treated in 2024 were included in the analysis.
resultsKRAS mutations were identified in 63.54% of patients, predominantly in codon 12 (70.49%) and codon 13 (14.75%). No significant associations were found between KRAS mutation status and factors such as sex, age, or tumor location. Nevertheless, KRAS mutations were more frequently observed in patients with left-sided colon tumors, contrasting with the findings described in the literature. KRAS mutations were associated with poorer prognosis, higher rates of metastases (particularly to the liver), and higher rates of resistance to conventional treatments, such as chemotherapy.
conclusionsThis study highlights the importance of KRAS mutation testing to support personalized, more effective treatment strategies to improve the prognosis of patients with metastatic colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.